Literature DB >> 23772079

Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1.

Arthur Weaver1, Orrin Troum, Michele Hooper, Andrew S Koenig, Sandeep Chaudhari, Jingyuan Feng, Deborah Wenkert.   

Abstract

OBJECTIVE: To determine whether disease activity and disability independently correlate with serious infection event (SIE) risk in a large rheumatoid arthritis (RA) cohort.
METHODS: The associations between SIE and Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in the Rheumatoid Arthritis Disease-Modifying Antirheumatic Drug Intervention and Utilization Study (RADIUS 1) cohort were evaluated using the Andersen-Gill model (a proportional HR model allowing > 1 event per patient).
RESULTS: Of 4084 patients with 347 SIE, 271 patients experienced ≥ 1 SIE. A 5-unit CDAI increase and 0.4-unit HAQ-DI increase corresponded to an increase in SIE risk with and without covariate adjustments. A 5-unit CDAI increase corresponded with a 7.7% increased SIE risk (adjusted HR 1.077, 95% CI 1.044-1.112, p < 0.0001) and a 0.4-unit HAQ-DI increase with a 30.1% increased risk (adjusted HR 1.301, 95% CI 1.225-1.381, p < 0.0001). Categorical analysis showed that more severe RA activity (even after controlling for disability) and disability were associated with an increased SIE risk.
CONCLUSION: Increased RA disease activity and disability were each associated with a significantly increased SIE risk in the RADIUS 1 cohort, which could not be completely accounted for by disability.

Entities:  

Keywords:  ANTIRHEUMATIC DRUGS; DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; INFECTION; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2013        PMID: 23772079     DOI: 10.3899/jrheum.121288

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis.

Authors:  Orit Barrett; Ella Abramovich; Jacob Dreiher; Victor Novack; Mahmoud Abu-Shakra
Journal:  Rheumatol Int       Date:  2017-03-12       Impact factor: 2.631

Review 2.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

3.  Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis.

Authors:  Haruki Sawada; Masei Suda; Ryo Rokutanda; Daiki Kobayashi; Kishimoto Mitsumasa; Masato Okada
Journal:  Rheumatol Int       Date:  2018-07-27       Impact factor: 2.631

4.  Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.

Authors:  Michael D George; Joshua F Baker; Beth Wallace; Lang Chen; Qufei Wu; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-10-07       Impact factor: 4.794

5.  Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.

Authors:  Michael D George; Joshua F Baker; Kevin Winthrop; Jesse Y Hsu; Qufei Wu; Lang Chen; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis
Journal:  Ann Intern Med       Date:  2020-09-22       Impact factor: 25.391

6.  Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.

Authors:  Mark T Osterman; William J Sandborn; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Anne M Robinson; Qian Zhou; James D Lewis
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

7.  Rheumatoid arthritis-related interstitial lung disease (RA-ILD): a possible association between disease activity and prognosis.

Authors:  Jorge Rojas-Serrano; Mayra Mejía; Pedro A Rivera-Matias; Denisse Herrera-Bringas; Diana I Pérez-Román; Renzo Pérez-Dorame; Heidegger Mateos-Toledo
Journal:  Clin Rheumatol       Date:  2022-02-03       Impact factor: 3.650

8.  Prevalence and microbiological characteristics of clinically infected foot-ulcers in patients with rheumatoid arthritis: a retrospective exploratory study.

Authors:  Pauline Fitzgerald; Heidi J Siddle; Michael R Backhouse; E Andrea Nelson
Journal:  J Foot Ankle Res       Date:  2015-08-16       Impact factor: 2.303

9.  One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Authors:  Leslie R Harrold; Heather J Litman; Katherine C Saunders; Kimberly J Dandreo; Bernice Gershenson; Jeffrey D Greenberg; Robert Low; Jeffrey Stark; Robert Suruki; Srihari Jaganathan; Joel M Kremer; Mohamed Yassine
Journal:  Arthritis Res Ther       Date:  2018-01-02       Impact factor: 5.156

10.  Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.

Authors:  Hisashi Yamanaka; Johan Askling; Niklas Berglind; Stefan Franzen; Thomas Frisell; Christopher Garwood; Jeffrey D Greenberg; Meilien Ho; Marie Holmqvist; Laura Novelli Horne; Eisuke Inoue; Kaleb Michaud; Dimitrios A Pappas; George Reed; Deborah Symmons; Eiichi Tanaka; Trung N Tran; Suzanne M M Verstappen; Eveline Wesby-van Swaay; Fredrik Nyberg
Journal:  RMD Open       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.